Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.26 and traded as low as $0.2380. Northwest Biotherapeutics shares last traded at $0.2430, with a volume of 1,796,585 shares changing hands.
Northwest Biotherapeutics Stock Up 1.7%
The company’s fifty day simple moving average is $0.24 and its two-hundred day simple moving average is $0.26. The company has a market capitalization of $373.81 million, a price-to-earnings ratio of -4.05 and a beta of -0.56.
Northwest Biotherapeutics (OTCMKTS:NWBO – Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter. The firm had revenue of $0.13 million for the quarter.
Northwest Biotherapeutics Company Profile
Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.
Further Reading
- Five stocks we like better than Northwest Biotherapeutics
- What Are Dividend Challengers?
- dLocal Falls Despite Blowout Q3 Results—What Investors Are Missing
- Basic Materials Stocks Investing
- Ondas Holdings Signals a Rebound as Drone Demand Soars
- Best Stocks Under $5.00
- Disney’s 2026 Outlook Brightens Under Iger’s Magic Touch
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
